Lexicon Pharmaceuticals | LXRX - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Abbott USD 68M 26M 2026-03
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.18B 4.3B 2026-03
Akebia Therapeutics 362.52M 357.69M 2026-03
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
AstraZeneca USD 484M 181M 2025-12
BioMarin Pharmaceutical USD 14.96M 12.18M 2026-03
Coherus Biosciences USD 2.25M 76K 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Esperion Therapeutics USD 22.64M 585K 2025-12
Halozyme Therapeutics USD 5.51M 597K 2026-03
Illumina USD 26M 1000K 2025-12
Insmed USD 20.08M 517K 2026-03
Ironwood Pharmaceuticals USD 8.74M 506K 2024-12
J&J USD 43M 25M 2026-03
Lexicon Pharmaceuticals USD 2.03M 124K 2025-12
MacroGenics USD 3.34M 2.54M 2025-09
MannKind USD 12.43M 1.44M 2026-03
Merck USD 479M 67M 2026-03
Moderna USD 11.49B 36B 2026-03
Novartis USD 343M 39M 2026-03
PTC Therapeutics USD 2.87B 2.82B 2026-03
Puma Biotechnology USD 3.37M 11K 2024-06
Sarepta Therapeutics USD 20.84M 13.28M 2025-12
Thermo Fisher Scientific USD 354M 11M 2026-03
Ultragenyx Pharmaceutical USD 21M 2M 2026-03
United Therapeutics USD 3.1M 100K 2025-12
Vanda Pharmaceuticals -1.37B 1.97B 2025-12